AgingResearch.NewsJoin free

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical

CompanyChina

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical develops 4 assets, the furthest in phase 3 (TAB014 in neovascular age-related macular degeneration). Mostly small molecule and antibody acting on KDR; based in China.

4
Assets
Furthest stage
Phase 3
5
Trials
1
Signal

Pipeline

4

  • TAB014

    Neutralizes VEGF-A to inhibit abnormal blood vessel growth and vascular leakage in the retina.

    Phase 3, Antibody, neovascular age-related macular degeneration, age-related macular degeneration (Phase 1), Partner

  • BRIMOCHOL PF

    Fixed-dose combination of brimonidine and carbachol to induce pupil constriction for presbyopia.

    Phase 2, Small molecule, presbyopia

  • CARBACHOL PF

    Cholinergic agonist inducing pupillary miosis to increase depth of focus for presbyopia.

    Phase 2, Small molecule, presbyopia

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials6
  • Signals2
  • Similar companies6

Intelligence